Page 59 - ITPS-7-2

INNOSC Theranostics and
Pharmacological Sciences Cardiac metabolism in health and disease

doi: 10.1089/ars.2015.6291 66. Meerson FZ. On the mechanism of compensatory
hyperfunction and insufficiency of the heart. Cor Vasa.
57. Young LH, Coven DL, Russell RR 3 . Cellular and molecular
rd
regulation of cardiac glucose transport. J Nucl Cardiol. 1961;3:161-177.
2000;7(3):267-276. 67. Sandler H, Dodge HT. Left ventricular tension and stress in
man. Circ Res. 1963;13:91-104.
doi: 10.1016/s1071-3581(00)70016-x
doi: 10.1161/01.res.13.2.91
58. Young LH, Renfu Y, Russell R, et al. Low-flow ischemia
leads to translocation of canine heart GLUT-4 and GLUT-1 68. Hood WP Jr., Rackley CE, Rolett EL. Wall stress in the
glucose transporters to the sarcolemma in vivo. Circulation. normal and hypertrophied human left ventricle. Am J
1997;95(2):415-422. Cardiol. 1968;22(4):550-558.
doi: 10.1161/01.cir.95.2.415 doi: 10.1016/0002-9149(68)90161-6
59. Brosius FC 3 , Nguyen N, Egert S, et al. Increased 69. Grossman W, Jones D, McLaurin LP. Wall stress and patterns
rd
sarcolemmal glucose transporter abundance in myocardial of hypertrophy in the human left ventricle. J Clin Invest.
ischemia. Am J Cardiol. 1997;80(3A):77A-84A. 1975;56(1):56-64.
doi: 10.1016/s0002-9149(97)00460-8 doi: 10.1172/JCI108079
60. Apstein CS, Opie LH. A challenge to the metabolic approach 70. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP.
to myocardial ischaemia. Eur Heart J. 2005;26(10):956-959. Prognostic implications of echocardiographically
determined left ventricular mass in the Framingham Heart
doi: 10.1093/eurheartj/ehi200
Study. N Engl J Med. 1990;322(22):1561-1566.
61. Selker HP, Beshansky JR, Griffith JL, et al. Study design
for the immediate myocardial metabolic enhancement doi: 10.1056/NEJM199005313222203
during initial assessment and treatment in emergency care 71. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH.
(IMMEDIATE) trial: A double-blind randomized controlled Relation of left ventricular mass and geometry to morbidity
trial of intravenous glucose, insulin, and potassium for acute and mortality in uncomplicated essential hypertension. Ann
coronary syndromes in emergency medical services. Am Intern Med. 1991;114(5):345-352.
Heart J. 2012;163(3):315-322.
doi: 10.7326/0003-4819-114-5-345
doi: 10.1016/j.ahj.2012.02.002
72. Christe ME, Rodgers RL. Altered glucose and fatty acid
62. Selker HP, Udelson JE, Massaro JM, et al. One-year outcomes oxidation in hearts of the spontaneously hypertensive rat.
of out-of-hospital administration of intravenous glucose, J Mol Cell Cardiol. 1994;26(10):1371-1375.
insulin, and potassium (GIK) in patients with suspected doi: 10.1006/jmcc.1994.1155
acute coronary syndromes (from the IMMEDIATE
[Immediate myocardial metabolic enhancement during 73. Zhang YB, Meng YH, Chang S, Zhang RY, Shi C. High
initial assessment and treatment in emergency care] trial). fructose causes cardiac hypertrophy via mitochondrial
Am J Cardiol. 2014;113(10):1599-1605. signaling pathway. Am J Transl Res. 2016;8(11):4869-4880.
doi: 10.1016/j.amjcard.2014.02.010 74. Lionetti V, Stanley WC, Recchia FA. Modulating
fatty acid oxidation in heart failure. Cardiovasc Res.
63. Wahlstrom KL, Hansen HF, Kvist M, et al. Effect of remote 2011;90(2):202-209.
Ischaemic preconditioning on perioperative endothelial
dysfunction in non-cardiac surgery: A randomised clinical doi: 10.1093/cvr/cvr038
trial. Cells. 2023;12(6):911. 75. Neubauer S. The failing heart--an engine out of fuel. N Engl
doi: 10.3390/cells12060911 J Med. 2007;356(11):1140-1151.
64. Kakavand H, Saadatagah S, Naderian M, et al. Evaluating doi: 10.1056/NEJMra063052
the role of intravenous pentoxifylline administration on 76. Beer M, Seyfarth T, Sandstede J, et al. Absolute concentrations
primary percutaneous coronary intervention success of high-energy phosphate metabolites in normal,
rate in patients with ST-elevation myocardial infarction hypertrophied, and failing human myocardium measured
(PENTOS-PCI). Naunyn Schmiedebergs Arch Pharmacol. noninvasively with (31) P-SLOOP magnetic resonance
2023;396(3):557-565.
spectroscopy. J Am Coll Cardiol. 2002;40(7):1267-1274.
doi: 10.1007/s00210-022-02368-3
doi: 10.1016/s0735-1097(02)02160-5
65. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy 77. Neubauer S, Remkes H, Spindler M, et al. Downregulation
of the heart: A new therapeutic target? Circulation. of the Na(+)-creatine cotransporter in failing human
2004;109(13):1580-1589.
myocardium and in experimental heart failure. Circulation.
doi: 10.1161/01.CIR.0000120390.68287.BB 1999;100(18):1847-1850.

Volume 7 Issue 2 (2024) 10 doi: 10.36922/itps.2302